Andreas Köpke, CEO
WITA Proteomics AG, spun out of WITA GmbH in March 2001, is a proteomics company identifying disease-related proteins for the diagnostic, drug development and predictive toxicology markets using its High Performance Proteomics technology.
The High Performance Proteomics platform provides ultra-high-resolution analytical and preparative 2-D gel electrophoresis, mass spectral analysis by MALDI-TOF or ESI/MS/MS, sequence analysis, bioinformatics and database compilation.
WITA Proteomics’ research programs range from the study of protein markers and identification of novel drug targets for schizophrenia, depression and Lyme disease to the development of a liver toxicology database for preclinical screening of drug candidates.
Agreement for the identification of important proteins for the development of new food products using the High Performance Proteomics technology platform: Nestlé SA
Strategic marketing agreement to market WITA’s high-resolution proteomics platform in North America: Genomics One Corp.
Agreement to jointly identify, validate and develop potential drug targets for pharmaceutical and biotechnology partners: Pharmagene plc
Other partners include Raven Biotech, B.R.A.H.M.S Diagnostica GmbH, Janssen Pharmaceutica NV (a unit of Johnson & Johnson), Schering AG and other European and North American pharmaceutical companies and academic laboratories.